Results 131 to 140 of about 744,838 (140)

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy

Molecular Genetics and Metabolism, 2007
Toya Ohashi, Teruo Kitagawa, Yoshikatsu Eto   +2 more
exaly  

Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease

Molecular Genetics and Metabolism, 2018
Kohtaro Minami, Noboru Tanaka, Hideto Morimoto   +2 more
exaly  

Spotlight on Agalsidase Beta in Fabry Disease1

BioDrugs, 2012
Dene Simpson, Gillian M Keating
exaly  

Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease

JIMD Reports, 2015
Michael J Gambello, Gustavo Maegawa, Neal Weinreb   +2 more
exaly  

Fabry disease in children: agalsidase-beta enzyme replacement therapy

Clinical Genetics, 2013
Ulla Feldt-Rasmussen, Line Borgwardt, Martin Ballegaard   +2 more
exaly  

Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme

Genetics in Medicine, 2008
Dominique P Germain, C Ronald Scott
exaly  

Effect of Reduced Agalsidase Beta Dosage in Fabry Patients: The Australian Experience

JIMD Reports, 2011
Mark Thomas, Kathleen Nicholls, Ian Chapman   +2 more
exaly  

Effects of Switching from Agalsidase Beta to Agalsidase Alfa in 10 Patients with Anderson-Fabry Disease

JIMD Reports, 2012
Massimo Imbriaco, Giancarlo Messalli, Eleonora Riccio   +2 more
exaly  

Agalsidase Beta Clinical Trials and Long Term Experience

2010
Robert J. Hopkin, Carlos E Prada
exaly  

Treatment with agalsidase beta during pregnancy in Fabry disease

Journal of Obstetrics and Gynaecology Research, 2010
exaly